{"id":"ch14-18-cho","safety":{"commonSideEffects":[{"rate":null,"effect":"Pain (neuropathic and procedural)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Capillary leak syndrome"}]},"_chembl":{"chemblId":"CHEMBL5715932","moleculeType":null,"molecularWeight":"614.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ch14.18/CHO binds to GD2 (disialoganglioside), a tumor-associated antigen highly expressed on neuroblastoma cells. By cross-linking tumor cells with immune effector cells (NK cells, macrophages, neutrophils), it activates antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), leading to tumor cell destruction. The CHO designation indicates the antibody is produced in Chinese Hamster Ovary cells.","oneSentence":"Ch14.18/CHO is a chimeric monoclonal antibody that targets GD2 on neuroblastoma cells and engages immune effector cells to promote antibody-dependent cellular cytotoxicity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:43.336Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"High-risk neuroblastoma (in combination with cytokine therapy)"}]},"trialDetails":[{"nctId":"NCT02914405","phase":"PHASE1","title":"Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2018-05-24","conditions":"Neuroblastoma","enrollment":44},{"nctId":"NCT02258815","phase":"PHASE2","title":"CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma","status":"COMPLETED","sponsor":"University Children's Hospital Tuebingen","startDate":"2010-08","conditions":"Neuroblastoma Recurrent","enrollment":35},{"nctId":"NCT02743429","phase":"PHASE2","title":"Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma","status":"UNKNOWN","sponsor":"University Medicine Greifswald","startDate":"2015-03-27","conditions":"Neuroblastoma","enrollment":40},{"nctId":"NCT01704716","phase":"PHASE3","title":"High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2002-02","conditions":"Neuroblastoma","enrollment":3300},{"nctId":"NCT01704872","phase":"PHASE1","title":"ch14.18/CHO Bridging Study","status":"COMPLETED","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2005-07","conditions":"Neuroblastoma","enrollment":16},{"nctId":"NCT01701479","phase":"PHASE1, PHASE2","title":"Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)","status":"UNKNOWN","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2012-01","conditions":"Neuroblastoma","enrollment":288}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":29,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mouse-human chimeric monoclonal anti-GD2 Immunoglobulin G1 (IgG1) antibody","anti GD2 antibody","Dinutuximab beta EUSA","Qarziba®","Chimeric 14.18 anti-GD2 monoclonal antibody produced in Chinese hamster ovary cells"],"phase":"phase_3","status":"active","brandName":"Ch14.18/CHO","genericName":"Ch14.18/CHO","companyName":"University Hospital Southampton NHS Foundation Trust","companyId":"university-hospital-southampton-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ch14.18/CHO is a chimeric monoclonal antibody that targets GD2 on neuroblastoma cells and engages immune effector cells to promote antibody-dependent cellular cytotoxicity. Used for High-risk neuroblastoma (in combination with cytokine therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}